A set of plasma peptides were targeted with selected reaction monitoring (SRM) on an Altis Plus and also with parallel reaction monitoring (PRM) on a Stellar. The maximum concurrency of the assay was 624 transitions for the Altis, but only 128 precursors for the Stellar. The quantitative performance of the assays was characterized with a matrix-matched dilution curve of human into chicken plasma, where the Stellar had LOQs and LODs that were on average 12x and 2x better than the Altis. Targeted assays were created for absolute quantitation of the PQ500 light and heavy peptides for a 60 samples-per-day (SPD) and 100 SPD throughputs. The quantitative performance of these assays was characterized using dilution curves of the heavy standards spiked into 300 ng of human plasma with the Stellar mass spectrometer. Both assays gave good results, with the 60 SPD assay having LOQs about 1.6x better on average than the 100 SPD assay. Targeted assays were created for label-free quantitation of E. coli spiked into 200 ng of HeLa. Two 60 samples-per-day methods were created, one with 397 peptides, and another with 1302 peptides. These assays were based off of a gas-phase-fractionation (GPF) data independent acquisition (DIA) experiment using the Thermo Fisher Scientific Stellar mass spectrometer. The quantitative performance of these assays was characterized over the range of E. coli amounts from 100 ng to 0.78 ng. Both size assays gave good results, with the n=397 assay having LOQs about 1.2x better on average than the n=1302 assay.